A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment

被引：1
|
作者：
Marbury, T. [1 ]
Stonerock, R. [1 ]
Acharya, M. [2 ]
Gonzalez, M. [2 ]
Jiao, J. [2 ]
Breeding, J. [3 ]
Haqq, C. [3 ]
Molina, A. [3 ]
Tran, N. [3 ]
机构：
[1] Orlando Clin Res Ctr, Orlando, FL USA
[2] Johnson & Johnson Pharmaceut, Res & Developlment, Raritan, NJ USA
[3] OrthoBiotech Oncol Res & Dev, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72006-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S501 / S501
页数：1
相关论文
共 50 条
  • [1] An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment
    Nakamaru, Yoshinobu
    Kakubari, Masae
    Yoshida, Kaori
    Akimoto, Makoto
    Kondo, Kazuoki
    CLINICAL THERAPEUTICS, 2020, 42 (09) : 1699 - 1714
  • [2] A single-dose pharmacokinetic (PK) study of lasofoxifene in healthy volunteers and subjects with mild or moderate hepatic impairment
    Bramson, C
    Ouellet, D
    Roman, D
    Randinitis, E
    Gardner, MJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1189 - 1189
  • [3] A Phase 1 Single Dose Open-label Reduced/staged Pharmacokinetic (PK) and Safety Study of Abiraterone Acetate (AA) in Men With Impaired Renal Function
    Marbury, T.
    Stonerock, R.
    Tran, N.
    Gonzalez, M.
    Jiao, J.
    Breeding, J.
    Haqq, C. M.
    Molina, A.
    Acharya, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S502 - S502
  • [4] Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
    Kenneth Duchin
    Giorgio Senaldi
    Vance Warren
    Thomas Marbury
    Kenneth Lasseter
    Hamim Zahir
    Clinical Drug Investigation, 2018, 38 : 1001 - 1009
  • [5] Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
    Duchin, Kenneth
    Senaldi, Giorgio
    Warren, Vance
    Marbury, Thomas
    Lasseter, Kenneth
    Zahir, Hamim
    CLINICAL DRUG INVESTIGATION, 2018, 38 (11) : 1001 - 1009
  • [6] A Phase-I, Open-Label, Single-Dose Study of the Pharmacokinetics of Buparlisib in Subjects With Mild to Severe Hepatic Impairment
    Csonka, Denes
    Hazel, Katharine
    Waldron, Edward
    Lorenzo, Sebastien
    Duval, Vincent
    Trandafir, Lucia
    Kobalava, Zhanna D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (03): : 316 - 323
  • [7] A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
    Ou, Ying C.
    Preston, Richard A.
    Marbury, Thomas C.
    Tang, Zhiyu
    Novotny, William
    Tawashi, Manal
    Li, Ta-Kai
    Sahasranaman, Srikumar
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1355 - 1363
  • [8] Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning
    Nakamaru, Yoshinobu
    Kakubari, Masae
    Yoshida, Kaori
    Akimoto, Makoto
    Todorovic, Vesna
    Greis, Thomas
    Kondo, Kazuoki
    CLINICAL THERAPEUTICS, 2020, 42 (08) : 1467 - +
  • [9] A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment
    Bramson, C
    Ouellet, D
    Roman, D
    Randinitis, E
    Gardner, MJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01): : 29 - 36
  • [10] Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
    Smith, William B.
    Hall, Jesse
    Berg, Jolene
    Kazimir, Michal
    Yamamoto, Amy
    Lee, Caroline
    Walker, Susan
    Marbury, Thomas C.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345